Nine-year follow-up of patients with relapsed follicular lymphoma after nonmyeloablative allogeneic stem cell transplant and autologous transplant was written by Khouri, Issa F.;Milton, Denai R.;Gulbis, Alison M.;Jabbour, Elias J.;Nastoupil, Loretta;Ledesma, Celina;Anderlini, Paolo;Bashir, Qaiser;Daher, May;Im, Jin S.;Iyer, Swaminathan P.;Marin, David;Mehta, Rohtesh S.;Olson, Amanda L.;Popat, Uday R.;Qazilbash, Muzaffar;Saini, Neeraj;Samaniego, Felipe;Rondon, Gabriela;Medeiros, Jeffrey L.;Champlin, Richard E.. And the article was included in Clinical Cancer Research in 2021.Recommanded Product: 16506-27-7 The following contents are mentioned in the article:
To compare outcomes between patients with relapsed follicular lymphoma who received a nonmyeloablative allogeneic stem cell transplant (alloSCT) and those who received an autologous transplant (autoSCT). We evaluated 194 patients with follicular lymphoma who received an alloSCT (n = 98) or autoSCT (n = 96) at MD Anderson Cancer Center (Houston, TX). The transplant type used was based on donor availability and by Medicare reimbursement guidelines. Patients who received an alloSCT were enrolled in four consecutive trials in which they received Hudarabine1 cyclophosphamide (or bendamustine), and rituximab conditioning. autoSCT patients received R-BEAM (rituximab, carmustine, etoposide, cytarabine, and mclphalan). The median follow-up of survivors was 108 mo for the alloSCT group and 102 mo for the autoSCT group. Overall survival was significantly better for patients who received an alloSCT compared with those who received an autoSCT (62% vs. 46%; P = 0.048). Similarly, progression-free survival rates were 52% in patients who received an alloSCT and 31% in those who received an autoSCT (P < 0.001), and the 8-yr relapse rates were 11% and 43%, resp. (P < 0.0001). Only three patients in the alloSCT group relapsed beyond 3.5 years. In the alloSCT group, the rates for grade 2 to 4 acute graft-versushost disease (GVHD)1 grade 3 to 4 acute GVHD1 and extensive chronic GVHD were 22%, 9%, and 38%, resp. In the autoSCT group, the 8-yr incidence of secondary myelodysplasia was 11%. Nonrelapse mortality was similar between the two groups (15% vs. 11% at 8 years; P = 0.27). This study shows that alloSCT is curative and confers superior survival compared with autoSCT in patients with follicular lymphoma. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Recommanded Product: 16506-27-7).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.Recommanded Product: 16506-27-7
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem